RS52212B - Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors - Google Patents

Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Info

Publication number
RS52212B
RS52212B RS20110551A RSP20110551A RS52212B RS 52212 B RS52212 B RS 52212B RS 20110551 A RS20110551 A RS 20110551A RS P20110551 A RSP20110551 A RS P20110551A RS 52212 B RS52212 B RS 52212B
Authority
RS
Serbia
Prior art keywords
alkyl
optionally substituted
cycloalkyl
phenyl
groups
Prior art date
Application number
RS20110551A
Other languages
Serbian (sr)
Inventor
Rui Xu
Dengming Xiao
Jun Liang
Brian Safina
Christine Chabot
Ian S. Mitchell
James F. Blake
Nicholas C. Kallan
Keith Lee Spencer
Josef R. Bencsik
Birong Zhang
Steven Do
Anna L. Banka
Stephen T. Schlachter
Eli. W. Wallace
Original Assignee
Array Biopharma, Inc.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52212(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc., Genentech, Inc. filed Critical Array Biopharma, Inc.
Priority claimed from PCT/US2007/072876 external-priority patent/WO2008006032A1/en
Publication of RS52212B publication Critical patent/RS52212B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Jedinjenje Formule I:i razloženi enantiomeri, razloženi diastereomeri i soli, gde:R1 je Me;R2 je H;R5 je H A je G je fenil opciono zamenjen jednom do četiri R9 grupe ili 5- ili 6-člani heteroaril opciono zamenjen halogenom;R6 i R7 su nezavisno H, OCH3, ( C3-C6 cikloalkil)-(CH2), ( C3-C6 cikloalkil)-(CH2CH2), V-(CH2)0-1 gde V je 5- ili 6-člani heteroaril, W-(CH2)))1-2 gde W je fenil opciono zamenjen sa F, Cl, Br, I, OMe, CF3 ili Me, C3-C6-cikloalkil opciono zamenjen sa C1-C3 alkil grupom ili O(C1-C3 alkil), hidroksi-(C3-C6-cikloalkil), fluoro-(C3-C6-cikloalkil), CH(CH3)CH(OH)fenil grupom, 4- do 6-člani heterocikl opciono zamenjen sa F, OH, C1-C3 alkil, ciklopropilmetil ili C(=O)(C1-C3 alkil) grupom, ili C1-C6-alkil opciono zamenjen sa jednom ili više grupa nezavisno odabranih medu OH, okso, O(C1-C6-alkil), CN, F, NH2, NH(C1-C6-alkil), N (C1-C6-alkil)2, ciklopropil, fenil, imidazolil, piperidinil, pirolidinil, morfolinil, tetrahidrofuranil, oksetanil ili tetrahidropiranil,ili R6 i R7 zajedno sa azotom za koji su prikačeni formiraju 4- do 7-člani heterociklični prsten opciono zamenjen sa jednom ili više grupa nezavisno odabranih medu OH, halogen, okso, CF3, CH2CF3, CH2CH2OH, O(C1-C3 alkil), C(=O)CH3, NH2, NHMe, N(Me)2, S(O)2CH3, ciklopropilmetil i C1-C3 alkil grupe; Rc i Rd su H, R8 je H;svaki R9 je nezavisno halogen, C1-C6-alkil, C3-C6-cikloalkil, O-(C1-C6-alkil), CF-3, OCF3, S(C1-C6-alkil),CN, OCH2-fenil, CH2O-fenil, NH2, NH-(C1-C6-alkil), N-(C1-C6-alkil)2, piperidin, pirolidin, CH2F,CHF2, OCH2F, OCHF2, OH, SO2(C1-C6-alkil), C(O)NH2, C(O)NH(C1-C6-alkil), i C(O)N(C1-C6-alkil)2;R10 je H. Prijava sadrži još 16 patentnih zahteva.A compound of Formula I: and decomposed enantiomers, decomposed diastereomers and salts, wherein: R 1 is Me, R 2 is H, R 5 is HA is G is phenyl optionally substituted with one to four R 9 groups or 5- or 6-membered heteroaryl optionally substituted with halogen; and R7 are independently H, OCH3, (C3-C6 cycloalkyl) - (CH2), (C3-C6 cycloalkyl) - (CH2CH2), V- (CH2) 0-1 wherein V is 5- or 6-membered heteroaryl, W - (CH2))) 1-2 wherein W is phenyl optionally substituted with F, Cl, Br, I, OMe, CF3 or Me, C3-C6-cycloalkyl optionally substituted with a C1-C3 alkyl group or O (C1-C3 alkyl ), hydroxy- (C3-C6-cycloalkyl), fluoro- (C3-C6-cycloalkyl), CH (CH3) CH (OH) phenyl group, 4- to 6-membered heterocycle optionally substituted with F, OH, C1-C3 alkyl, cyclopropylmethyl or a C (= O) (C1-C3 alkyl) group, or C1-C6-alkyl optionally substituted with one or more groups independently selected from OH, oxo, O (C1-C6-alkyl), CN, F, NH2, NH (C1-C6-alkyl), N (C1-C6-alkyl) 2, cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, oxetanyl or tetrahydropyranyl, or R6 and R7 together with the nitrogen to which they are attached form a 4- to 7-membered heterocyclic ring optionally substituted with one or more groups independently selected from OH, halogen, oxo, CF3, CH2CF3, CH2CH2OH, O (C1-C3 alkyl), C (= O ) CH3, NH2, NHMe, N (Me) 2, S (O) 2CH3, cyclopropylmethyl and C1-C3 alkyl groups; Rc and Rd are H, R8 is H, each R9 is independently halogen, C1-C6-alkyl, C3-C6-cycloalkyl, O- (C1-C6-alkyl), CF-3, OCF3, S (C1-C6- alkyl), CN, OCH2-phenyl, CH2O-phenyl, NH2, NH- (C1-C6-alkyl), N- (C1-C6-alkyl) 2, piperidine, pyrrolidine, CH2F, CHF2, OCH2F, OCHF2, OH, SO2 (C1-C6-alkyl), C (O) NH2, C (O) NH (C1-C6-alkyl), and C (O) N (C1-C6-alkyl) 2; R10 is H. The application contains more 16 patent claims.

RS20110551A 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors RS52212B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
PCT/US2007/072876 WO2008006032A1 (en) 2006-07-06 2007-07-05 Cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Publications (1)

Publication Number Publication Date
RS52212B true RS52212B (en) 2012-10-31

Family

ID=38686743

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110551A RS52212B (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Country Status (35)

Country Link
EP (4) EP2402325B1 (en)
JP (4) JP5266216B2 (en)
KR (5) KR20150051240A (en)
CN (2) CN102816124A (en)
AR (3) AR061842A1 (en)
AT (1) ATE524447T1 (en)
AU (1) AU2007269060B2 (en)
BR (3) BRPI0713923B8 (en)
CA (2) CA2836316A1 (en)
CL (1) CL2007001993A1 (en)
CO (1) CO6150161A2 (en)
CR (1) CR10600A (en)
CY (1) CY1112117T1 (en)
DK (2) DK2402325T3 (en)
ES (3) ES2554252T3 (en)
HK (3) HK1160638A1 (en)
HR (1) HRP20110908T1 (en)
HU (1) HUE026237T2 (en)
IL (2) IL196028A (en)
IN (1) IN2014KN02886A (en)
MA (1) MA31655B1 (en)
MX (4) MX366319B (en)
MY (1) MY147364A (en)
NO (1) NO342346B1 (en)
NZ (3) NZ610633A (en)
PL (2) PL2402325T3 (en)
PT (1) PT2049501E (en)
RS (1) RS52212B (en)
RU (2) RU2478632C2 (en)
SG (4) SG188905A1 (en)
SI (2) SI2049501T1 (en)
TW (2) TWI402266B (en)
UA (1) UA95641C2 (en)
WO (1) WO2008006040A1 (en)
ZA (1) ZA200900070B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147628A (en) 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006039A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
JP5628028B2 (en) 2007-07-05 2014-11-19 アレイ バイオファーマ、インコーポレイテッド Pyrimidylcyclopentane as an AKT protein kinase inhibitor
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
BRPI0813993A2 (en) 2007-07-05 2015-06-16 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
ES2426092T3 (en) 2008-01-09 2013-10-21 Array Biopharma, Inc. 5H-Cyclopenta [d] pyrimidines as AKT protein kinase inhibitors
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
BRPI0906798A2 (en) * 2008-01-09 2015-07-14 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN102015708B (en) 2008-01-09 2014-03-26 阵列生物制药公司 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2821378A1 (en) * 2010-12-23 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
PL2694073T3 (en) * 2011-04-01 2019-06-28 Genentech, Inc. Combinations of akt and mek inhibitors for treating cancer
JP6143739B2 (en) * 2011-04-01 2017-06-07 ジェネンテック， インコーポレイテッド Combination of AKT inhibitor compound and vemurafenib, and method of use
US20140031259A1 (en) * 2011-04-01 2014-01-30 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
SG11201407591PA (en) 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028589B1 (en) * 2012-05-17 2022-08-23 Genentech, Inc. HYDROXYLATED CYCLOPENTYPYRIMIDINE, ITS MANUFACTURING PROCESS AND ITS INTERMEDIARIES
DK2861583T3 (en) * 2012-05-17 2016-10-03 Array Biopharma Inc METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
AU2013262548B2 (en) * 2012-05-17 2017-09-21 Genentech, Inc. Amorphous form of an AKT inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
SI2850054T1 (en) 2012-05-17 2018-06-29 Genentech, Inc. Process for making amino acid compounds
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN104968363A (en) * 2012-12-07 2015-10-07 综合医院公司 Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP6340162B2 (en) * 2012-12-20 2018-06-06 日東電工株式会社 Apoptosis inducer
JP6374503B2 (en) 2013-11-15 2018-08-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Process for the preparation of pyrimidinylcyclopentane compounds
US10457648B2 (en) * 2014-09-26 2019-10-29 Genentech Inc. Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
TW202329972A (en) 2016-08-10 2023-08-01 瑞士商赫孚孟拉羅股份公司 Pharmaceutical compositions comprising akt protein kinase inhibitors
CN112154146A (en) * 2018-03-06 2020-12-29 西奈山伊坎医学院 Serine threonine kinase (AKT) degradation/disruption compounds and methods of use
CN113194941A (en) 2018-12-19 2021-07-30 基因泰克公司 Treatment of breast cancer using a combination therapy comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
BR112021011894A2 (en) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited PHARMACEUTICAL COMPOSITION
CN117964620A (en) 2019-01-29 2024-05-03 南京正大天晴制药有限公司 AKT inhibitors
US20220249511A1 (en) 2019-03-29 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
WO2020210337A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
WO2021254920A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
WO2022017449A1 (en) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
TWI750905B (en) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 Thiazole compounds as protein kinase inhibitors
KR20230035773A (en) * 2021-09-06 2023-03-14 연세대학교 산학협력단 A Composition for Preventing or Treating Atopic Dermatitis Comprising an Inhibitor of AKT Signaling Pathway as an Active Ingredient
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (en) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-dichloro-6,7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride preparation method
CN117677614A (en) * 2021-12-17 2024-03-08 中国医药研究开发中心有限公司 Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (en) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1998030546A1 (en) * 1997-01-08 1998-07-16 F. Hoffmann-La Roche Ag TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES
ES2152902B1 (en) * 1999-07-27 2001-08-16 Medichem Sa VENLAFAXINE OBTAINING PROCEDURE
DE60134990D1 (en) * 2000-08-18 2008-09-04 Millenium Pharmaceuticals Inc QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
AU2001291013A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60239864D1 (en) * 2001-03-30 2011-06-09 King Pharmaceuticals Inc CONDENSED THIOPHENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CHRONIC PAIN
DE60231439D1 (en) * 2001-12-06 2009-04-16 Merck & Co Inc MITOTIC KINESINE HEMMER
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
RU2006121990A (en) * 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) ACT PROTEINKINASE INHIBITORS
DE602005020611D1 (en) * 2004-04-28 2010-05-27 Vertex Pharma COMPOSITIONS SUITED AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MY147628A (en) * 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006039A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors

Also Published As

Publication number Publication date
NZ610633A (en) 2014-12-24
KR20090030333A (en) 2009-03-24
MX366319B (en) 2019-07-05
EP2049501A1 (en) 2009-04-22
JP5266216B2 (en) 2013-08-21
KR20140093291A (en) 2014-07-25
EP2399909A1 (en) 2011-12-28
ES2372774T3 (en) 2012-01-26
BR122013028005B1 (en) 2021-04-06
ATE524447T1 (en) 2011-09-15
CL2007001993A1 (en) 2008-06-20
EP2966065A3 (en) 2016-03-02
JP2013177470A (en) 2013-09-09
AU2007269060B2 (en) 2014-02-20
SG10201802127UA (en) 2018-04-27
MA31655B1 (en) 2010-09-01
NZ573732A (en) 2012-03-30
NO342346B1 (en) 2018-05-07
AU2007269060A1 (en) 2008-01-10
RU2012155606A (en) 2014-06-27
TWI402266B (en) 2013-07-21
KR101495408B1 (en) 2015-02-25
MY147364A (en) 2012-11-30
CN102816124A (en) 2012-12-12
IL241705A0 (en) 2015-11-30
BR122013028005B8 (en) 2021-05-25
RU2009103900A (en) 2010-08-20
CN101578273B (en) 2012-11-14
EP2402325A3 (en) 2012-06-13
HK1160134A1 (en) 2012-08-10
CA2836316A1 (en) 2008-01-10
IL196028A0 (en) 2009-09-01
MX2008016202A (en) 2009-02-11
KR20130029364A (en) 2013-03-22
RU2478632C2 (en) 2013-04-10
HUE026237T2 (en) 2016-06-28
JP2009542723A (en) 2009-12-03
SI2402325T1 (en) 2015-12-31
BR122013028012B1 (en) 2021-04-06
KR101578877B1 (en) 2016-02-22
JP5836294B2 (en) 2015-12-24
MX2019008117A (en) 2019-09-04
EP2049501B1 (en) 2011-09-14
EP2402325A2 (en) 2012-01-04
CA2656622A1 (en) 2008-01-10
CY1112117T1 (en) 2015-11-04
KR20150051240A (en) 2015-05-11
UA95641C2 (en) 2011-08-25
EP2966065A2 (en) 2016-01-13
PL2049501T3 (en) 2012-02-29
SG185980A1 (en) 2012-12-28
CR10600A (en) 2009-02-20
AR061842A1 (en) 2008-09-24
BR122013028012B8 (en) 2021-05-25
DK2402325T3 (en) 2015-12-07
BRPI0713923B8 (en) 2021-05-25
BRPI0713923B1 (en) 2020-09-29
CO6150161A2 (en) 2010-04-20
SG188905A1 (en) 2013-04-30
DK2049501T3 (en) 2011-12-12
ES2554228T3 (en) 2015-12-17
PL2402325T3 (en) 2016-01-29
BRPI0713923A2 (en) 2013-07-02
NZ597647A (en) 2013-08-30
MX337843B (en) 2016-03-22
HK1126768A1 (en) 2009-09-11
TW201332994A (en) 2013-08-16
CN101578273A (en) 2009-11-11
PT2049501E (en) 2011-12-30
HRP20110908T1 (en) 2012-02-29
IL196028A (en) 2017-02-28
ES2554252T3 (en) 2015-12-17
KR101178672B1 (en) 2012-09-07
HK1160638A1 (en) 2012-08-10
AR093810A2 (en) 2015-06-24
CA2656622C (en) 2017-09-12
SG184706A1 (en) 2012-10-30
JP2013091670A (en) 2013-05-16
AR109424A2 (en) 2018-11-28
EP2402325B1 (en) 2015-08-26
EP2399909B1 (en) 2015-08-26
NO20090581L (en) 2009-04-06
ZA200900070B (en) 2010-03-31
SI2049501T1 (en) 2012-01-31
JP2014231530A (en) 2014-12-11
IN2014KN02886A (en) 2015-05-08
TW200817373A (en) 2008-04-16
WO2008006040A1 (en) 2008-01-10
KR20130141717A (en) 2013-12-26

Similar Documents

Publication Publication Date Title
RS52212B (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
RS52210B (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CY1118879T1 (en) TRIAZINE COMPOUNDS AS P13 AND MTOR MODULAR INHIBITORS
PE20050232A1 (en) METHOD AND COMPOSITIONS TO TREAT RHEUMATOID ARTHRITIS
AR048652A1 (en) 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS
AR046711A1 (en) 5-7-DIAMINOPIRAZOLO [4,3D] PYRIMIDINS AS INHIBITORS OF THE PDE-5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF HYPERTENSIONS
CY1118723T1 (en) Benzothiazole and azabenzothiazole compounds useful as suspensions of kinase
AR053652A1 (en) DERIVATIVES OF INDOL AS PROTEIN QUINASE INHIBITORS. PHARMACEUTICAL COMPOSITIONS
RS52596B (en) Substituted amide derivatives as protein kinase inhibitors
ATE338461T1 (en) PYRAZOLEPYRIMIDE INFUNGICIDES
ECSP066414A (en) MALONAMIDE DERIVATIVES THAT BLOCK GAMA-SECRETASA ACTIVITY
HUT60733A (en) Process for producing new n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide derivatives and pharmaceutical compositions comprising such compounds
HN2005000370A (en) PYRID-PYRIMIDINE DERIVATIVES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CO5611147A2 (en) USEFUL NICOTINAMIDE DERIVATIVES AS INHIBITORS P38
ATE479667T1 (en) THIAZOLYL-BASED COMPOUNDS SUITABLE AS KINASE INHIBITORS
MEP12608A (en) Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
RS51189B (en) Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase
JO2652B1 (en) 1,2,4,5Tetrahydro - 3H - benzazepine compounds , a process for their preparation and pharmaceutical compositions containing them
EA200602176A1 (en) DERIVATIVES OF TETRAHYDRO-ISOHINOLYL-SULPHONAMIDES, THEIR RECEIVING AND USING IN THERAPY
AR058110A1 (en) PIPERIDINE DERIVATIVES
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6160324A2 (en) REPLACED HETEROCICLES CONTAINING NITROGEN AS INHIBITORS OF THE ADP PLAQUETARY RECEIVER
AR055666A1 (en) INNTR INHIBITORS
AR054072A1 (en) 3-AMINO ARILPROPIL INDOLES AS MONOAMINE REABSORTION INHIBITORS. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
CO5660263A2 (en) DERIVATIVES OF IMIDAZOL HETEROARIL SUBSTITUTED AS ANTAGONISTS OF THE GLUTAMATE RECEIVER